Answers are grounded in this paper and cite their sources.
This cross-sectional study describes national and regional Medicare spending and out-of-pocket costs for tafamidis from its approval in 2019 to 2021.
No takes yet. Share an insight, caveat, or question.
Blatt et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: